急性冠症候群市場 - 競合情勢

2024年には、世界16カ国で780万人以上の急性冠症候群（ACS）入院偶発症例が予測されています。ACS市場における有望な革新の開発には、新規の経口P2Yプリン受容体12（P2Y12）受容体阻害薬が含まれます。ACSのパイプラインには17の分子があります。第III相のパイプラインは3剤、次いで第II相の4つの薬剤です。

過去10年間で、ACSの治験施設数は米国が最も多く723施設、次いで中国が550施設以上となりました。過去10年間、北米とアジア太平洋では買収が最も一般的な取引形態でした。欧州ではライセンス契約が主流となりました。

当レポートでは、世界の急性冠症候群市場について調査し、疾患の概要とともに、治験動向、パイプライン概要、将来の見通しなどを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 病気の情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬剤の評価

• 主な市販薬
• 作用機序別概要
• 分子タイプ別概要
• 製品プロファイルと売上予測

第5章 価格設定と償還評価

• 年間治療費
• 価格設定と償還までの時間

第6章 パイプライン薬剤の評価

• 中期から後期段階のパイプライン薬剤
• 開発段階別概要
• 作用機序別概要
• 分子タイプ別概要
• 薬剤固有の相転移成功率（PTSR）と承認可能性（LoA）
• 治療領域と適応症別のPTSRとLoA

第7章 臨床試験の評価

• 実績の概要
• 相別概要
• ステータス別概要
• 進行中および計画中の試験の相別概要
• 仮想コンポーネントの試験
• 地域の試験概要
• 地域別の単一国および多国間試験
• 相別のスポンサー上位20社
• ステータス別のスポンサー上位20社
• エンドポイントステータス別概要
• 人種と民族別概要
• 登録データ
• 治験実施施設上位20カ国
• 世界のトップ20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引の情勢

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in Acute coronary syndrome therapeutics.

• In 2024, more than 7.8 million hospitalized incident cases of ACS are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for ACS.
• Promising innovator developments in the ACS market include newer oral P2Y purinoceptor 12 (P2Y12)-receptor inhibitors.
• There are 17 molecules in the pipeline for ACS. The Phase III pipeline consists of three drugs, followed by four drugs in Phase II.
• Over the past 10 years, the US has hosted the highest number of trial sites for ACS, at 723 trial sites, followed by China with more than 550 trial sites.
• During the past decade, acquisitions were the most common deal type in North America and in Asia-Pacific. In Europe, licensing agreements were the predominant deal type.

Scope

GlobalData's Acute coronary syndrome: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Acute coronary syndrome market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Acute coronary syndrome market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer